REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Fg Capital Sp. z o.o. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Secondary Activities: Other Heavy and Civil Engineering Construction | Other Building Equipment Contractors | Other Depository Credit Intermediation | All Other Nondepository Credit Intermediation | Trusts, Estates, and Agency Accounts | Offices of Real Estate Agents and Brokers | Real Estate Property Managers | Management of Companies and Enterprises
Full name: Fg Capital Sp. z o.o. Profile Updated: May 28, 2024
Buy our report for this company USD 19.99 Most recent financial data: 2020 Available in: English & Polish Download a sample report

Fg Capital Sp. z o.o. is based in Poland, with the head office in Gdansk. It operates in the Research and Development in Biotechnology (except Nanobiotechnology) industry. It was first established on November 21, 2017. Its total assets decreased by 13.19% over the same period.

Headquarters
Ul. Al. Grunwaldzka 26/5
Gdansk; Pomorskie; Postal Code: 80-229

Contact Details: Purchase the Fg Capital Sp. z o.o. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Fg Capital Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Fg Capital Sp. z o.o. report to view the information.
Incorporation Date:
November 21, 2017
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
75%
Purchase this report to view the information.
25%
Company Performance
Financial values in the chart are available after Fg Capital Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
16.51%▲
Net Profit (Loss) for the Period
16.51%▲
Total assets
-13.19%▼
Total equity
-13.3%▼
Return on Equity (ROE)
0.6%▲
Quick Ratio
-16%▼

Similar companies

Selvita S.A.
 
"Novo Nordisk Pharma" Sp. z o.o.
Celon S.A.
 
Mabion S.A.
Selvita Services Sp. z o.o.
 
Sartorius Stedim Poland Sp. z o.o.
Windprojekt Sp. z o.o.
 
Wilandt Institute
Wet-Family Sp. z o.o.
 
Wekzmed Sp. z o.o.
Warsaw Genomics Sp. z o.o.
 

To view more information, Request a demonstration of the EMIS service

USD 19.99
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo